MESOBLAST LTD
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MESO in the last 30 days.
See all $MESO insider activity →Mesoblast reported FY GAAP EPS of -$0.04, beating estimates by $0.08, while revenue of $120.25M missed by $65.62M. Revenue grew 599.1% year-over-year. The company also received FDA approval for a new potency assay for Ryoncil.
Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.
Mesoblast (NASDAQ: MESO, ASX: MSB) completed patient treatment in its Phase 3 trial for rexlemestrocel-L, a therapy for chronic low back pain, with 350 patients enrolled. The company reported US$36M in Q4 revenue for Ryoncil, totaling US$115M for the year. Mesoblast also secured US$103M in cash after extinguishing debt. The company is pursuing FDA approvals for expanded uses of Ryoncil and rexlemestrocel-L.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning MESO (MESOBLAST LTD). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent MESO coverage spans earnings, technology and market movers.
Revenue miss outweighs EPS beat, likely pressuring the stock lower.
Positive regulatory win may boost sales and market confidence.
The dosing completion enhances trial credibility and may boost the stock ahead of the 12‑month read‑out.
Approval validates MSC platform and may drive revenue growth.
The trial updates and regulatory clearance could boost investor confidence and drive the stock higher ahead of upcoming data readouts.
AlphAI scores every news story that mentions MESO with an AI model for sentiment and relevance, and aggregates insider trades from MESOBLAST LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Mesoblast reported FY GAAP EPS of -$0.04, beating estimates by $0.08, while revenue of $120.25M missed by $65.62M. Revenue grew 599.1% year-over-year. The company also received FDA approval for a new potency assay for Ryoncil.
1 min readSeveral biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.
3 min readMesoblast (NASDAQ: MESO, ASX: MSB) completed patient treatment in its Phase 3 trial for rexlemestrocel-L, a therapy for chronic low back pain, with 350 patients enrolled. The company reported US$36M in Q4 revenue for Ryoncil, totaling US$115M for the year. Mesoblast also secured US$103M in cash after extinguishing debt. The company is pursuing FDA approvals for expanded uses of Ryoncil and rexlemestrocel-L.
2 min readIn 2024-2026, longevity advancements include FDA-approved MSC products, accelerated peptide approvals, and AI-designed drugs. GLP-1 medicines show cardiometabolic benefits. A gray market of wellness peptides exists, with FDA advisory votes on compounding. Mesoblast's Ryoncil gained FDA approval, and Longeveron's Laromestrocel targets aging-related conditions. Life Biosciences initiated a partial cellular reprogramming trial. Key players include Altos Labs, NewLimit, and Life Biosciences, with va
3 min readMesoblast is conducting trials for RYONCIL in acute GVHD and Duchenne muscular dystrophy, with results expected in 2027. The company anticipates double-digit revenue growth and is pursuing approvals for rexlemestrocel-L in chronic low back pain and REVASCOR in heart failure. Mesoblast expects lower cash burn in fiscal 2027 and has a $125M credit facility.
2 min readMESOBLAST LTD (MESO) furnished an SEC Form 6-K — earnings release. MESOBLAST REPORTS SUBSTANTIAL REVENUE GROWTH TO US$120M RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 New York, USA: August 26 and Melbourne, Australia: August 27, 2026: Mesobla
2 min readMesoblast (MESO) shares rose about 9.5% after the company said it completed patient treatment in the MSB-DR004 pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain from degenerative disc disease. The trial enrolled 350 patients versus 300 planned. The primary endpoint targets durable pain reduction at 12 months, with FDA RMAT designation and a BLA submission targeted for Q3 2027.
3 min readMesoblast Limited (Nasdaq:MESO) said it reached its target of at least 300 treated patients in the MSB-DR004 pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain due to degenerative disc disease. The primary endpoint compares pain reduction at 12 months vs sham. Top-line results are expected mid-2027.
2 min readAustralia’s S&P/ASX 200 fell 0.41% to 8,770.2 by midday Monday as Middle East tensions and IMF warnings weighed on sentiment. The IMF cut Australia’s 2026 growth forecast to 1.9% and flagged inflation near 4%. Coles slid on a reported Greencross deal; Santos and Woodside were softer; Mesoblast was upgraded to buy with a $4.45 target.
7 min readASX futures pointed to a 0.49% rise at the open after Wall Street ended higher, supported by AI and chip stocks. The ASX 200 rose 0.5% on Friday to 8,806, led by mining and financials. Telstra fell 1.6%, WiseTech 1.8%, while Mesoblast rose 6% on US$115m FY2026 revenue. Geopolitical Iran tensions and oil moves weighed on sentiment.
4 min read
